Biotechnology is not only about the development of new active substances.

Offering innovative therapeutics quickly, in sufficient quantities and at affordable prices is an ongoing challenge for drug manufacturing. For the production of personalized medicine therapeutics, such as CAR-T cells or cancer vaccines, as well as mRNA vaccines, the fragile genetic material needs to be packaged in a stable nanoparticle. While LNPs are used for this purpose, their availability is restricted by the limited throughput capacity of conventional LNP encapsulation systems – a high-cost factor and bottleneck for the development and delivery of important, life-saving drugs.

LEON’s FR-Jet devices NANOme and NANOus enable a highly efficient approach to aseptic, GMP-compliant encapsulation of active ingredients into nanoparticles, as well as rapid scale-up from preclinical scale to commercial manufacturing. NANOme is optimized for small-scale individual patient and clinical trial-size production. NANOus is a fully-automated, aseptic device enabling the LNP-encapsulation of APIs from medium- to large-scale with high throughput using process analytical technology (PAT).

Targeting users such as CDMOs or biotech and pharma companies, we aim to reduce length of time and expenses of process development while massively increasing production efficiency. These are crucial prerequisites for improving access to advanced therapies for the benefit of patients.